Prosecution Insights
Last updated: August 18, 2026

Examiner: CUNNINGCHEN, KATHLEEN MARY

Tech Center 1600 • Art Units: 1641 1646

This examiner grants 60% of resolved cases

Performance Statistics

60.4%
Allow Rate
At TC average
92
Total Applications
+64.8%
Interview Lift
1450
Avg Prosecution Days
Based on 53 resolved cases, 2023–2026

Rejection Statute Breakdown

3.1%
§101 Eligibility
15.8%
§102 Novelty
29.8%
§103 Obviousness
32.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18324406 METHODS FOR MODULATING HOST CELL SURFACE INTERACTIONS WITH HUMAN CYTOMEGALOVIRUS Non-Final OA Genentech, Inc.
17999352 ENGINEERED ANTI-PROSTATE STEM CELL ANTIGEN FUSION PROTEINS AND USES THEREOF Final Rejection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
17595015 NON-HLA MARKERS OF TRANSPLANT REJECTION Final Rejection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
17265934 MODULATING PTPN2 TO INCREASE IMMUNE RESPONSES AND PERTURBING GENE EXPRESSION IN HEMATOPOIETIC STEM CELL LINEAGES Non-Final OA President and Fellows of Harvard College
17767818 RECOMBINANT POLYPEPTIDES FOR REGULATABLE CELLULAR LOCALIZATION Final Rejection The Board of Trustees of the Leland Stanford Junior University
18256241 BYSTANDER PROTEIN VACCINES Final Rejection IOGENETICS, LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month